Hypertension Exacerbates Severity and Outcomes of COVID-19 in Elderly Patients: A Retrospective Observational Study

Abstract

Objective

To evaluate the impact of hypertension on the clinical outcome of COVID-19 patients aged 60 years old and older.

Methods

This single-center retrospective cohort study enrolled consecutive COVID-19 patients aged 60 years old and older, who were admitted to Liyuan Hospital from January 1, 2020 to April 25, 2020. All included patients were divided into two groups: hypertension and nonhypertension group. The baseline demographic characteristics, laboratory test results, chest computed tomography (CT) images and clinical outcomes were collected and analyzed. The prognostic value of hypertension was determined using binary logistic regression.

Results

Among the 232 patients included in the analysis, 105 (45.3%) patients had comorbid hypertension. Compared to the nonhypertension group, patients in the hypertension group had higher neutrophil-to-lymphocyte ratios, red cell distribution widths, lactate dehydrogenase, high-sensitivity C-reactive protein, D-dimer and severity of lung lesion, and lower lymphocyte counts (all P<0.05). Furthermore, the hypertension group had a higher proportion of intensive care unit admissions [24 (22.9%) vs. 14 (11.0%), P=0.02) and deaths [16 (15.2%) vs. 3 (2.4%), P<0.001] and a significantly lower probability of survival (P<0.001) than the nonhypertension group. Hypertension (OR: 4.540, 95% CI: 1.203–17.129, P=0.026) was independently correlated with all-cause in-hospital death in elderly patients with COVID-19.

Conclusion

The elderly COVID-19 patients with hypertension tend to have worse conditions at baseline than those without hypertension. Hypertension may be an independent prognostic factor of poor clinical outcome in elderly COVID-19 patients.

Keywords

COVID-19 / SARS-CoV-2 / hypertension / prognosis / mortality / risk factor

References

[1] BedfordJ, EnriaD, GieseckeJ, et al.. COVID-19: towards controlling of a pandemic. Lancet, 2020, 395(10229): 1015

[2] World Health Organization, Coronavirus disease (COVID-2019) situation reports. Available from: https://covid19.who.int/

[3] GuanWJ, NiZY, HuY, et al.. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020, 382(18): 1708-1720

[4] Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease ControlPrevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi (Chinese), 2020, 41(2): 145-151

[5] ChenT, WuD, ChenH, et al.. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ, 2020, 368: 1091

[6] DuY, TuL, ZhuP, et al.. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A Retrospective Observational Study. Am J Respir Crit Care Med, 2020, 201(11): 1372-1379

[7] ZhangJJ, DongX, CaoYY, et al.. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 2020, 75(7): 1730-1741

[8] OnderG, RezzaG, BrusaferroS. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA, 2020, 323(18): 1775-1776

[9] LiX, XuS, YuM, et al.. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol, 2020, 146(1): 110-118

[10] GuanWJ, LiangWH, ZhaoY, et al.. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J, 2020, 55(5): 2000547

[11] ZhouF, YuT, DuR, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, 395(10229): 1054-1062

[12] WangD, HuB, HuC, et al.. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, 323(11): 1061

[13] WangZ, ChenZ, ZhangL, et al.. Status of hypertension in China: results from the China hypertension survey, 2012–2015. Circulation, 2018, 137(22): 2344-2356

[14] HuangG, GongT, WangG, et al.. Timely diagnosis and treatment shortens the time to resolution of coronavirus disease (COVID-19) pneumonia and lowers the highest and last CT scores from sequential chest CT. AJR Am J Roentgenol, 2020, 215(2): 367-373

[15] Emami A, Javanmardi F, Akbari A, et al. Survival rate in hypertensive patients with COVID-19. Clin Exp Hypertens, 2020:1–4

[16] XiongTY, HuangFY, LiuQ, et al.. Hypertension is a risk factor for adverse outcomes in patients with coronavirus disease 2019: a cohort study. Ann Med, 2020, 52(7): 361-366

[17] PanW, ZhangJ, WangM, et al.. Clinical Features of COVID-19 in Patients with Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients. Hypertension, 2020, 76(3): 732-741

[18] YangQ, ZhouY, WangX, et al.. Effect of hypertension on outcomes of adult inpatients with COVID-19 in Wuhan, China: a propensity score-matching analysis. Respir Res, 2020, 21(1): 172

[19] HuangS, WangJ, LiuF, et al.. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res, 2020, 43(8): 824

[20] ZhouX, ZhuJ, XuT. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors. Clin Exp Hypertens, 2020, 42(7): 656-660

[21] ShiQ, ZhangX, JiangF, et al.. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes Care, 2020, 43(7): 1382-1391

[22] Nehme J, Borghesan M, Mackedenski S, et al. Cellular senescence as a potential mediator of COVID-19 severity in the elderly. Aging Cell, 2020:e13237

[23] ZieglerCGK, AllonSJ, NyquistSK, et al.. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell, 2020, 181(5): 1016-1035

[24] WeiskopfD, SchmitzKS, RaadsenMP, et al.. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol, 2020, 5(48): eabd2071

[25] ItaniHA, McMasterWG, SalehMA, et al.. Activation of human T Cells in Hypertension: studies of humanized mice and hypertensive humans. Hypertension, 2016, 68(1): 123

[26] McMasterWG, KiraboA, MadhurMS, et al.. Inflammation, immunity, and hypertensive end-organ damage. Circ Res, 2015, 116(6): 1022-1033

[27] FestJ, RuiterTR, KoerkampBG, et al.. The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: the Rotterdam study. Eur J Epidemiol, 2019, 34(5): 463-470

[28] Idris-KhodjaN, MianMO, ParadisP, et al.. Dual opposing roles of adaptive immunity in hypertension. Eur Heart J, 2014, 35(19): 1238-1244

[29] LinJ, XuR, YunL, et al.. A risk prediction model for renal damage in a hypertensive Chinese Han population. Clin Exp Hypertens, 2019, 41(6): 552-557

[30] BazickHS, ChangD, MahadevappaK, et al.. Red cell distribution width and all-cause mortality in critically ill patients. Crit Care Med, 2011, 39(8): 1913-1921

[31] HenryBM, BenoitJL, BenoitS, et al.. Red blood cell distribution width (RDW) predicts COVID-19 severity: a prospective, observational study from the cincinnati SARS-CoV-2 emergency department cohort. Diagnostics (Basel), 2020, 10(9): 618

[32] TaneriPE, Gomez-OchoaSA, LlanajE, et al.. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol, 2020, 35(8): 763-773

[33] RanJ, SongY, ZhuangZ, et al.. Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China. Hypertens Res, 2020, 43(11): 1267-1276